Information and analysis earlier than you hear about it on CNBC and others. Declare your 1-week free trial to StreetInsider Premium here.
- EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM AGAINST MULTIPLE RNA TARGETS ACROSS TAKEDA’S KEY INDICATIONS
- EVOTEC RECEIVES RESEARCH FUNDING AND IS ELIGIBLE FOR SUCCESS-BASED MILESTONES AND TIERED ROYALTIES
HAMBURG, GERMANY / ACCESSWIRE / March 22, 2021 / Evotec SE (Frankfurt Inventory Change: EVT, MDAX/TecDAX, ISIN: DE0005664809) right this moment introduced that the Firm has entered right into a multi-RNA goal alliance with Takeda Pharmaceutical Firm Restricted (“Takeda”) with the objective to find and develop RNA focusing on small molecule therapeutics for extremely engaging targets which can be tough to deal with through extra typical approaches.
Evotec and Takeda will collectively determine and develop small molecules focusing on a spread of RNA targets aligned with Takeda’s analysis and growth areas. The collaboration will leverage Evotec’s in depth RNA focusing on platform to optimally determine promising RNA sequences to focus on with small molecule ligands that may be developed into probably first-in-class therapeutics.
Underneath the phrases of the settlement, Evotec will obtain important analysis funding and can be eligible to obtain discovery, pre-clinical, medical, business and gross sales milestone funds of as much as US$ 160 m per programme. Moreover, Evotec is entitled to tiered royalties on internet gross sales of any merchandise ensuing from the collaboration.
Dr Twine Dohrmann, Chief Scientific Officer of Evotec, commented: “Many extremely validated targets have confirmed to be intractable through typical protein focusing on approaches. For that reason, Evotec has been pioneering RNA focusing on methods and approaches for fairly a while. We’re very excited in regards to the alternative to collaborate with Takeda on this area as each corporations share the imaginative and prescient to collectively develop small molecule therapeutics in opposition to excessive worth RNA targets that can ship lengthy awaited therapeutics.”
“Takeda acknowledges focusing on RNA with small molecules as a promising new modality that has super potential for a lot wanted medicines for sufferers via modulating traditionally undruggable targets”, stated Dr Larry Hamann, Head, Drug Discovery Sciences, Takeda. “We’re excited to be working with Evotec and their spectacular capabilities.”
About Evotec’s RNA platform
The structure-based recognition of RNA tertiary constructions by RNA-targeted small molecules (“rSM”) gives a substitute for sequence-based approaches, akin to antisense oligonucleotides (“ASOs”). rSM approaches allow novel therapeutic potential by permitting to focus on extremely conserved components of RNA, creating pathways in instances the place the encoded protein can’t be focused conventionally, and unlocking the largely unexplored area of non-coding RNAs, which will also be illness drivers.
Evotec’s proprietary RNA focusing on platform is particularly designed to
- determine RNA tertiary structural parts the place rSM are in a position to bind with ample selectivity and affinity,
- uncover and develop appropriate rSM binders that probably ship orally obtainable medicine, and
- determine and ship proof-of-target engagement for disease-relevant RNA constructions, permitting biologically energetic rSM binders.
Evotec’s cutting-edge RNA small molecule platform builds on the well-established drug discovery routes inside Evotec and combines them with novel, extremely progressive applied sciences akin to third technology sequencing, sequencing-based construction elucidation of RNA molecules, which represent a first-class experience on this space.
ABOUT TAKEDA PHARMACEUTICAL COMPANY LIMITED
Takeda Pharmaceutical Firm Restricted (TSE: 4502/NYSE: TAK) is a worldwide, values-based, R&D-driven biopharmaceutical chief headquartered in Japan, dedicated to find and ship life-transforming remedies, guided by our dedication to sufferers, our individuals and the planet. Takeda focuses its R&D efforts on 4 therapeutic areas: Oncology, Uncommon Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We additionally make focused R&D investments in Plasma-Derived Therapies and Vaccines. We’re specializing in creating extremely progressive medicines that contribute to creating a distinction in individuals’s lives by advancing the frontier of recent remedy choices and leveraging our enhanced collaborative R&D engine and capabilities to create a strong, modality-diverse pipeline. Our staff are dedicated to enhancing high quality of life for sufferers and to working with our companions in well being care in roughly 80 international locations. For extra info, go to www.takeda.com.
ABOUT EVOTEC SE
Evotec is a drug discovery alliance and growth partnership firm centered on quickly progressing progressive product approaches with main pharmaceutical and biotechnology corporations, lecturers, affected person advocacy teams and enterprise capitalists. We function worldwide and our greater than 3,500 staff present the very best high quality stand-alone and built-in drug discovery and growth options. We cowl all actions from target-to-clinic to satisfy the business’s want for innovation and effectivity in drug discovery and growth (EVT Execute). The Firm has established a novel place by assembling top-class scientific specialists and integrating state-of-the-art applied sciences in addition to substantial expertise and experience in key therapeutic areas together with neuronal ailments, diabetes and issues of diabetes, ache and irritation, oncology, infectious ailments, respiratory ailments, fibrosis, uncommon ailments and ladies’s well being. On this foundation, Evotec has constructed a broad and deep pipeline of greater than 100 co-owned product alternatives at medical, pre-clinical and discovery phases (EVT Innovate). Evotec has established a number of long-term alliances with companions together with Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For extra info please go to www.evotec.com and comply with us on Twitter @Evotec.
Data set forth on this press launch accommodates forward-looking statements, which contain a lot of dangers and uncertainties. The forward-looking statements contained herein characterize the judgement of Evotec as of the date of this press launch. Such forward-looking statements are neither guarantees nor ensures, however are topic to a wide range of dangers and uncertainties, a lot of that are past our management, and which might trigger precise outcomes to vary materially from these contemplated in these forward-looking statements. We expressly disclaim any obligation or enterprise to launch publicly any updates or revisions to any such statements to mirror any change in our expectations or any change in occasions, situations or circumstances on which any such assertion relies.
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of World Company Communications & Advertising and marketing, Cellphone: +49.(0)40.56081-255, email@example.com
IR Contact Evotec SE:
Volker Braun, SVP Head of World Investor Relations & ESG, Cellphone: +49.(0)40.56081-775, firstname.lastname@example.org
SOURCE: Evotec AG
View supply model on accesswire.com: